NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia – PRNewswire

CONTEXT:  Blurring the lines of real-world research and traditional Phase 3, NovaBiotics announce their intravenous cysteamine bitartrate therapy (NM002) has become part of the REMAP-CAP initiative.  REMAP-CAP is a global Continue Reading

Posted On :

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine – Business Wire

CONTEXT:  Presentation of a retrospective study in migraine epidemiology in Southern Israel at the 7th Congress of the European Academy of Neurology (EAN).  Findings showed extreme variability in the prevalence Continue Reading

Posted On :